retatrutide nonalcoholic fatty liver disease trial nash Trial comparing time-restricted eating (TRE) vs. basic Calorie Oligonucleotide therapies for nonalcoholic steatohepatitis

Growing demand fuels gray market Despite the lack of robust data, demand for peptides grew

7 A Beth Israel study of 60 MS patients showed a 3.7% mean reduction in BMI, increased vitamin D levels (which is beneficial for MS), and no negative change in disability scores

By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy

Wegovy is specifically FDA-approved for chronic weight management in adults and adolescents aged 12 years and older with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia) [8] [9]